Goldman Sachs believes Piramal Pharma is well-placed within its coverage to deliver top-quartile profit growth driven by very high operating financial leverage.
Goldman Sachs believes Piramal Pharma is well-placed within its coverage to deliver top-quartile profit growth driven by very high operating financial leverage.